EDP Sciences logo
Search
Menu
All issues Volume 85 / No 1-2 (January-April 2005) Lait, 85 1-2 (2005) 75-84 References
Free Access
Issue
Lait
Volume 85, Number 1-2, January-April 2005
International Symposium on Propionibacteria and Bifidobacteria: dairy and probiotic applications
Page(s) 75 - 84
DOI https://doi.org/10.1051/lait:2005003
References of Lait 85 75-84
  1. Adams M.C., Huang Y., Kotula L., Blake R.J., Garg M.L., The efficacy of a potential new probiotic, Propionibacterium jensenii 702, to correct vitamin B12 levels in an in vivo deficient animal model, Asia Pac. J. Clin. Nutr. 26 (2002) 261.
  2. Agger E.M., Anderson P., Tuberculosis subunit vaccine development: on the role of interferon-$\gamma$, Vaccine 19 (2001) 2298-2302 [CrossRef].
  3. Aldwell F.E., Tucker I.G., de Lisle G.W., Buddle B.M., Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculsois in mice, Infect. Immunity 71(2003) 101-108.
  4. Anderson P., TB vaccines: progress and problems, Trends Immunol. 22 (2001) 160-168 [CrossRef].
  5. Anderson P., Askard D., Ljungqvist L., Bentzon M.W., Heron I., T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis, Infect. Immunology 59 (1991) 1558-1563.
  6. Brandt L., Cunha J.F., Olsen A.W., Chilima B., Hirsch P., Appelberg R., Andersen P., Failure of Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis, Infect. Immunity 70 (2002) 672-678.
  7. Charteris W.P., Kelly P.M., Morelli L., Collins J.K., Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract, J. Appl. Microbiol. 84 (1998) 759-768 [CrossRef].
  8. Conway P.L., Gorbach S.L., Goldin B.R., Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells, J. Dairy Sci. 70 (1987) 1-12.
  9. Del Giudice G., Podda A., Rappuoli R., What are the limits of adjuvanticity?, Vaccine 20 (2002) S38-S41.
  10. Doherty M.T., Olsen A.W., Van Pinxteren L., Andersen P., Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis, Infect. Immunity 70 (2002) 3111-3121.
  11. Elhay M.J., Anderson P., Immunological requirements for a subunit vaccine against tuberculosis, Immunol. Cell Biol. 75 (1997) 595-603.
  12. Erickson K.L., Hubbard N.E., Probiotic immunomodulation in health and disease, J. Nutr. 130 (2000) 403S-409S.
  13. Famularo G., Moretti S., Marcellini S., De Simone C., Stimulation of immunity by probiotics, in: Fuller R. (Ed.), Probiotics 2: Applications and practical aspects, Chapman and Hall, London, UK, 1997, pp. 133-161.
  14. Fatkenheuer G., Taelman H., Lepage P., Schwenk A., Wenzel R., The return of tuberculosis, Diag. Microbiol. Infect. Dis. 34 (1999) 139-146.
  15. Flaminio M.J.B.F., Rush B.R., Shuman W., Immunologic function in horses after non-specific immunostimulant administration, Vet. Immunol. Immunopath. 63 (1998) 303-315.
  16. Gheorghiu M.R., Lagranderie M., Balazuc A.M., Stabilisation of BCG vaccines. New approaches to stabilisation of vaccine potency, Dev. Biol. Stand. 87 (1996) 251-261.
  17. Guerin N., Evaluation of BCG and new vaccines against tuberculosis, Pediat. Pulm. S16 (1997) 286-287.
  18. Huang Y., Adams M.C., An in vitro model for investigating intestinal adhesion of potential dairy propionibacteria probiotic strains using cell line C2BBe1, Lett. Appl. Microbiol. 36 (2003) 213-216.
  19. Huang Y., Adams M.C., In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria, Int. J. Food Microbiol. 91 (2004) 253-260 [CrossRef].
  20. Huang Y., Kotula L., Adams M.C., The in vivo assessment of safety and gastrointestinal survival of an orally administered novel probiotic, Propionibacterium jensenii 702, in a male Wistar rat model, Food Chem. Toxicol. 41 (2003) 1781-1787.
  21. Kaufmann S.H.E., Anderson P., Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine, Chem. Immunol. 70 (1998) 21-59.
  22. Kaufmann S.H.E., Hess J., Immune response against Mycobacterium tuberculosis: implications for vaccine development, J. Biotechnol. 83 (2000) 13-17 [CrossRef].
  23. Linbald D.B., Elhay M.J., Silva R., Appelberg R., Anderson P., Adjuvant modulation of immune responses to tuberculosis subunit vaccines, Infect. Immunity 65 (1997) 623-629.
  24. Marin M.L., Tejada-Simon M.V., Lee J.H., Murtha J., Ustunol Z., Pestka J.J., Stimulation of cytokine production in clonol macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus, J. Food Prot. 61 (1998) 859-864.
  25. Megid J., Peraçolli M.T.S., Curi P.R., Zanetti C.R., Cabrera W.H., Vassao R., Ito F.H., Effect of the Bacillus of Calmette-Guérin, Propionibacterium acnes and avridine as immunomodulators in antirabies vaccination of mice using the Fuenzalida-Palacios mouse brain vaccine, Vaccine 17 (1999) 2446-2452 [CrossRef].
  26. Megid J., Kaneno R., Nozaki C.N., Broto C.J.C., Almeida M.F., Increased interleukin-10 associated with low IL-6 concentration correlated with greater survival rates in mice infected by rabies virus vaccinated against it and immunomodulated with P. acnes, Comp. Immunol. Microbiol. Infect. Dis. 27 (2004) 393-411.
  27. Miettinen M., Matikainen S., Vuopio-Varkila J., Pirhonen J., Varkila K., Kurimoto M., Julkunen I., Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18 and gamma interferon production in human peripheral blood mononuclear cells, Infect. Immunity 66 (1998) 6058-6062.
  28. Murray P.J., Defining the requirements for immunological control of mycobacterial infections, Trends Microbiol. 7 (1999) 366-372 [CrossRef].
  29. Murray C.J.L., Salomon J.A., Modeling the impact of global tuberculosis strategies, Proc. Natl. Acad. Sci. USA. 95 (1998) 13881-13886 [CrossRef].
  30. Pouwels P.H., Leer R.J., Shaw M., Heijne den BakGlashouwer M., Tielen F.D., Smit E., Martinez B., Jore J., Conway P.L., Lactic acid bacteria as antigen delivery vehicles for oral immunisation purposes, Int. J. Food Microbiol. 41 (1998) 155-167 [CrossRef].
  31. Richter L., Kipp P.B., Transgenic plants as edible vaccines, Curr. Top. Microbiol. Immunol. 240 (1999) 159-176.
  32. Russell-Jones G.J., Oral vaccine delivery, J. Control. Release 65 (2000) 49-54 [CrossRef].
  33. Seeger J.F.M.L., Lactobacilli as live vaccine delivery vectors: progress and prospects, Trends Biotechnol. 20 (2002) 508-515 [CrossRef].
  34. Skjot R.L.V., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., Anderson P., Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens, Infect. Immunity 68 (2000) 214-220.
  35. Wang X., Brown I.L., Evans A.J., Conway P.L., The protective effects of high amylase maize (amylomaize) starch granules on the survival of Bifidobacterium sp. in the mouse intestinal tract, J. Appl. Microbiol. 87 (1999) 631-639 [CrossRef].
  36. Waterman S.R., Small P.L.C., Acid-sensitive enteric pathogens are protected from killing under extremely acidic conditions of pH 2.5 when they are inoculated onto certain solid food sources, Appl. Environ. Microbiol. 64 (1998) 3882-3886.
  37. Weldingh K., Andersen P., Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins, FEMS Immunol. Microbiol. 23 (1999) 159-164.
  38. World Health Organisation, Tuberculosis control and research strategies for the 1990's: memorandum from a WHO meeting, Bull. WHO 70 (1992) 17-21.
  39. World Health Organisation, The global health emergency, WHO report on the TB epidemic, Geneva Switzerland, 1994.
  40. Zarate G., Perez-Chaia A., Gonzalez S., Oliver G., Viability and B-galactosidase activity of dairy propionibacteria subjected to digestion by artificial gastric and intestinal fluids, J. Food Prot. 63 (2000) 1214-1221.